Pertussis antigens and use thereof in vaccination
CA 2539715 C · Owner: Glaxosmithkline Biologicals S.A. · Inventors: Castado, Cindy; Godfroid, Fabrice; Denoel, Philippe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic prophylactic and , therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins iron acquisition , proteins, lipoproteins adhesins and toxins/invasins.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2004 and granted February 24, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 1, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.